Inmune Bio Inc. (INMB) fundamentals score
The only approved products to date are topical and do not address the systemic issues of the disease, which is the focus of CORDStrom.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 4.6 out of 10, Weak long-term fundamentals
- Growth: 5.0/10
- Profitability: 3.3/10
- Financial health: 5.8/10
- Earnings quality: 7.0/10
- Valuation: 2.2/10
Scores are calculated from Inmune Bio Inc.’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10